Valuation: BioRestorative Therapies, Inc.

Market Cap 2.97M 2.64M 2.47M 2.25M 4.23M 286M 4.29M 29.83M 11.55M 146M 11.14M 10.9M 467M P/E 2026 *
-0.24x
P/E 2027 * -0.29x
Enterprise Value 2.97M 2.64M 2.47M 2.25M 4.23M 286M 4.29M 29.83M 11.55M 146M 11.14M 10.9M 467M EV / Sales 2026 *
2.11x
EV / Sales 2027 * 1.28x
Free-Float
90.44%
Yield 2026 *
-
Yield 2027 * -
1 day+2.40%
1 week-4.94%
Current month+2.40%
1 month-39.82%
3 months-69.06%
6 months-58.14%
Current year-89.85%
1 week 2.26
Extreme 2.26
2.68
1 month 2.26
Extreme 2.26
4.2
Current year 2.26
Extreme 2.26
25.6
1 year 2.26
Extreme 2.26
34.6
3 years 2.26
Extreme 2.26
73.4
5 years 2.26
Extreme 2.26
480
10 years 2.26
Extreme 2.26
400,800
Manager TitleAgeSince
Chief Executive Officer 28 27/08/2026
Director of Finance/CFO 38 27/08/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 28 12/06/2026
Director/Board Member 37 12/06/2026
Director/Board Member - 13/07/2026
Date Insider Type Main position Quantity % Market Cap. Importance
6/10/25 Free

Chief Technology Officer

23,438 0.2938%
6/10/25 Free

Chief Executive Officer

27,344 0.3427%
14/2/25 Other

Chief Technology Officer

768,979 11.1125%
Change 5-day change 1-year change 3-year change Capi.($)
-2.34%-4.94%-91.66%-94.24% 2.97M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+80.21% 60.14B
-2.54%-1.65%+4.86%+33.32% 48.15B
-2.44%-3.97%+29.59%+36.21% 44.25B
+1.90%+4.83%+356.86%+700.59% 43.99B
-1.39%+0.51%+7.95%+102.69% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-3.17%-8.81%-24.74%+336.89% 24.93B
Average +0.67%+0.73%+40.74%+136.39% 39.68B
Weighted average by Cap. +0.61%+1.83%+59.69%+153.07%

Financials

2026 *2027 *
Net sales 1.4M 1.25M 1.17M 1.06M 2M 135M 2.03M 14.12M 5.47M 68.89M 5.28M 5.16M 221M 2.31M 2.05M 1.92M 1.75M 3.3M 223M 3.34M 23.24M 9M 113M 8.68M 8.49M 364M
Net income -13.52M -12.01M -11.23M -10.24M -19.27M -1.3B -19.54M -136M -52.61M -663M -50.77M -49.67M -2.13B -15.56M -13.82M -12.92M -11.78M -22.17M -1.5B -22.48M -156M -60.52M -763M -58.41M -57.15M -2.45B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
02/10/26 US$2.276 -2.34% 8,572
30/09/26 US$2.330 0.00% 24,949
29/09/26 US$2.330 +0.87% 15,079
28/09/26 US$2.310 -9.41% 49,420
25/09/26 US$2.550 +1.59% 29,435
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.330USD
Average target price
160.00USD
Spread / Average Target
+6,766.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock